An Alzheimer's blood test: what it means for diagnosis
The earlier you know, the more you can do. The early and accurate diagnosis of Alzheimer’s disease has, until recently, been difficult and time-consuming. Today, medical innovation is shifting it into something as simple as a routine blood test. But what does this shift actually mean for patients, families, and clinicians on the ground?
What Are the Current Challenges in Alzheimer's Diagnostics?
Diagnosing Alzheimer's disease has historically been a lengthy and complex journey, meaning families often wait years for a clear answer¹. For patients and families, this prolonged uncertainty can delay planning and treatment.
:quality(90)/)
In the '90s, getting a clear biological diagnosis while someone was still alive was almost impossible outside of research. Doctors couldn't give my family clear answers or really tell us what to expect. We were pretty much left in the dark trying to figure out and navigate things on our own.
Today, a diagnosis usually involves cognitive examinations combined with specialized diagnostic tools:
Cerebrospinal Fluid (CSF) Analysis: Measures spinal fluid to detect markers that reflect tau tangles and amyloid plaques in the brain2
PET Scans (Positron Emission Tomography): Brain imaging to visualize disease-related protein deposits2
The Access Barrier: While highly reliable, these methods are invasive (CSF testing requires a lumbar puncture), expensive, and unavailable in primary care settings3, contributing to diagnostic delays where up to 75% of dementia cases remain undiagnosed globally1.
But a shift is happening.
Instead of waiting months for specialized testing, a simple blood test can now detect the early biological hallmarks of Alzheimer's disease. Here's what changes when diagnosis becomes faster and more accessible:
Less time waiting for answers: Instead of months of uncertainty, a routine blood draw can provide results faster and more accessibly than existing testing options. This clarity allows patients and families to start conversations about treatment, care, and the future, instead of waiting in limbo89.
Avoiding unnecessary invasive procedures: If blood test results are clear, patients may not need a lumbar puncture or PET scan. (In some cases, additional testing may still be recommended) 5,10.
The ability to plan with your loved ones: A clear diagnosis turns uncertainty into actionable steps. It provides a starting point for real decisions: where care will be received, what treatments might be explored, and how the family will prepare for what's ahead 6.
:quality(90)/)
Knowing early gave us a plan, for treatment, for therapy, for the future. That plan is what let me be a better caregiver.
:quality(90)/)
Having clear answers sooner would have allowed for better planning, such as creating a project plan for touring facilities and coordinating with specialists.
:quality(90)/)
Without a confirmed diagnosis, we couldn't access the resources or the research that could have helped her.
How does the Alzheimer's blood test work?
Instead of waiting months for a PET scan or lumbar puncture, a simple blood test can now detect early signs of Alzheimer's disease quickly and conveniently. Advanced testing technologies measure key protein markers in the blood, the same biomarkers clinicians look for in cerebrospinal fluid and brain imaging.
Three Advantages:
A Simple, Non-Invasive Process4:
Unlike traditional lumbar punctures or brain imaging, blood-based testing requires only a routine blood draw, which can reduce the physical discomfort and logistical barriers associated with CSF and PET testing.
High-Accuracy Disease Detection5:
Tests are now available that measure two key proteins, pTau217 and pTau181, that accumulate in Alzheimer's disease. These markers help clinicians determine whether cognitive symptoms are due to Alzheimer's pathology or another cause.
Genetic Risk Identification13:
Optional genetic risk identification can detect APOE4 carriers, who have a higher likelihood of developing Alzheimer's later in life (typically after age 65). This information helps families understand risk and plan preventive care conversations with their doctor.
Scalability in Daily Lab Workflows: These blood tests use equipment that labs already have in place for routine bloodwork 2,7. Once approved, health systems can quickly expand access without expensive upgrades, meaning more patients can get tested in their local clinics. 2,8
What could these tests mean for society and healthcare systems?
Easing healthcare bottlenecks: These tests offer the potential to remove long wait times for specialist appointments to confirm a diagnosis. Primary care doctors can order these blood tests directly, freeing up neurology appointments for patients who need complex care38.
Scalability for health systems: Uses existing automated laboratory infrastructure, allowing health systems to expand diagnostic access without building new capacity27.
Supporting long-term planning: An earlier, evidence-based result gives a better understanding of the societal burden and what is needed to create a better future89.
According to Dr. Ashton Harper, Global Medical Director for Neurosciences at Roche Diagnostics "A simple blood test enables quick, routine testing that can be done in primary care or out-of-hospital settings. Broad access to diagnostic testing enables timely diagnosis, empowering patients to start tailored management plans at the earliest possible time."
The Bigger Picture
Bringing high-precision blood biomarker testing into routine care is one part of a broader shift toward earlier, more accessible Alzheimer's diagnosis. Beyond the technology itself, this shift is about restoring something essential: time, clarity, and dignity for patients and their families.
:quality(90)/)
Reimagining the Alzheimer's diagnostic pathway isn't just about advancing technology; it's about giving patients and their families the time, clarity, and dignity they deserve. By bringing precision testing to routine care, we can help ensure that an early diagnosis opens the door to proactive support, better management, and hope for the future.
References:
Dumas A, et al. Rethinking the detection and diagnosis of Alzheimer's disease: Outcomes of a European Brain Council project. Aging Brain. 2023;4:100093.
Leuzy A, et al. Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays... Alzheimers Dement. 2023;19:2994-3004.
Suridjan I, et al. Blood-based biomarkers in Alzheimer's disease: Future directions for implementation. Alzheimers Dement (Amst). 2023;15:e12508.
Cabral-Miranda F. Blood-based biomarkers for neurodegenerative diseases: A narrative review. NeuroMarkers. 2026;100168.
Schindler SE, et al. Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer's Disease. Nat Rev Neurol. 2024;20:426-39.
Alcolea D et al. (2023). Neurology 101(4), 172–180. Paper available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10435056/.
Grothe MJ, et al. Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. Neurology. 2021;97:e1229-42.
Hampel H, et al. Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape. Neuron. 2023;111:2781-99.
Li Y, et al. Cost-effectiveness analysis of blood-based biomarker testing in the diagnosis of Alzheimer's disease pathology. J Prev Alzheimers Dis. 2026;13:100474.
Pahlke S, et al. Blood-based biomarkers for detecting Alzheimer's disease pathology in cognitively impaired individuals... Alzheimers Dement. 2025;21:e70828.
IHME. Brain Health Atlas Factsheet [Internet; cited 2026 July 13]. Available from: https://brainhealthatlas.org/factsheet
National Institute on Aging. Estimates of amyloid onset may predict Alzheimer's progression [Internet; cited 2026 Aug 13]. Available from: https://www.nia.nih.gov
National Institutes of Health Public Access [Internet; cited 2026 March 11] Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3044597/pdf/nihms268644.pdf
MC-24093
Key Data or Facts:
55 Million+ people worldwide are currently living with dementia11
Up to 75% of people with dementia remain undiagnosed globally1
10 to 20 Years: Biological changes of Alzheimer's begin years before symptoms appear12
:quality(90)/)
:quality(90)/)
:quality(90)/)